188 related articles for article (PubMed ID: 30562958)
1. Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles.
Meka AK; Jenkins LJ; Dàvalos-Salas M; Pujara N; Wong KY; Kumeria T; Mariadason JM; Popat A
Pharmaceutics; 2018 Dec; 10(4):. PubMed ID: 30562958
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Farooq MA; Xinyu H; Jabeen A; Ahsan A; Seidu TA; Kutoka PT; Wang B
Colloids Surf B Biointerfaces; 2021 Mar; 199():111523. PubMed ID: 33360624
[TBL] [Abstract][Full Text] [Related]
3. Mesoporous silica nanoparticles for drug and gene delivery.
Zhou Y; Quan G; Wu Q; Zhang X; Niu B; Wu B; Huang Y; Pan X; Wu C
Acta Pharm Sin B; 2018 Mar; 8(2):165-177. PubMed ID: 29719777
[TBL] [Abstract][Full Text] [Related]
4. Improving the solubility of vorinostat using cyclodextrin inclusion complexes: The physicochemical characteristics, corneal permeability and ocular pharmacokinetics of the drug after topical application.
Yang J; Ma Y; Luo Q; Liang Z; Lu P; Song F; Zhang Z; Zhou T; Zhang J
Eur J Pharm Sci; 2022 Jan; 168():106078. PubMed ID: 34838620
[TBL] [Abstract][Full Text] [Related]
5. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
6. Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats.
Wang Y; Tu S; Steffen D; Xiong M
J Pharm Pharm Sci; 2014; 17(4):583-602. PubMed ID: 25579435
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; Martínez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
[TBL] [Abstract][Full Text] [Related]
9. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Vorinostat for the Treatment of Disorders Affecting Brain.
Athira KV; Sadanandan P; Chakravarty S
Neuromolecular Med; 2021 Dec; 23(4):449-465. PubMed ID: 33948878
[TBL] [Abstract][Full Text] [Related]
11. Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy.
Chaudhary Z; Subramaniam S; Khan GM; Abeer MM; Qu Z; Janjua T; Kumeria T; Batra J; Popat A
Front Bioeng Biotechnol; 2019; 7():225. PubMed ID: 31620434
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Anti-Tumor Efficacy of Vorinostat Encapsulated Self-Assembled Polymeric Micelles in Solid Tumors.
Rompicharla SVK; Trivedi P; Kumari P; Muddineti OS; Theegalapalli S; Ghosh B; Biswas S
AAPS PharmSciTech; 2018 Oct; 19(7):3141-3151. PubMed ID: 30132129
[TBL] [Abstract][Full Text] [Related]
13. Liquid CO
Raza A; Sime FB; Cabot PJ; Roberts JA; Falconer JR; Kumeria T; Popat A
ACS Biomater Sci Eng; 2021 May; 7(5):1836-1853. PubMed ID: 33438994
[TBL] [Abstract][Full Text] [Related]
14. An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy.
Bhagat SD; Singh U; Mishra RK; Srivastava A
ChemMedChem; 2018 Oct; 13(19):2073-2079. PubMed ID: 30070768
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat (SAHA) and Breast Cancer: An Overview.
Wawruszak A; Borkiewicz L; Okon E; Kukula-Koch W; Afshan S; Halasa M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572928
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Dissolution, Cellular Membrane Permeability, and Anti-Inflammatory Response of Resveratrol-Encapsulated Mesoporous Silica Nanoparticles.
Juère E; Florek J; Bouchoucha M; Jambhrunkar S; Wong KY; Popat A; Kleitz F
Mol Pharm; 2017 Dec; 14(12):4431-4441. PubMed ID: 29094948
[TBL] [Abstract][Full Text] [Related]
18. Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method.
Yang G; Li Z; Wu F; Chen M; Wang R; Zhu H; Li Q; Yuan Y
Int J Nanomedicine; 2020; 15():1661-1675. PubMed ID: 32210559
[TBL] [Abstract][Full Text] [Related]
19. In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.
Konsoula R; Jung M
Int J Pharm; 2008 Sep; 361(1-2):19-25. PubMed ID: 18562136
[TBL] [Abstract][Full Text] [Related]
20. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
